Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Researchers Should Use ACR/EULAR Definition of RA Remission in Clinical Studies

Vanessa Caceres  |  June 3, 2022

In clinical trials, rheumatologists should use the ACR/EULAR definition for rheumatoid arthritis (RA) remission instead of the Disease Activity Score-28-CRP (DAS28-CRP), according to David Felson, MD, MPH, professor of medicine, Boston University School of Medicine.

Dr. Felson

This is because patients may still have swollen joints and not actually be in remission under the DAS28 criteria. Dr. Felson addressed the challenges of defining RA remission during the inaugural ACR-FDA Summit, held online in May.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Felson was part of an ACR/EULAR committee that developed a provisional definition of remission in 2011.1 The ACR/EULAR criteria included two ways of defining remission. One was a Boolean-based definition that required patients to have a tender and swollen joint count equal to or less than 1, a C-reactive protein (CRP) level equal to or less than 1 mg/dL and a patient global assessment of arthritis activity equal to or less than 1 (on a 0 to 10 scale). The second was a Simplified Disease Activity Index score equal to or less than 3.3.

Patient-reported outcomes (PROs) have been shown to be the most sensitive for demonstrating outcomes, Dr. Felson said. The committee’s research at the time also found that the DAS28-CRP was not an acceptable definition of remission because it did not provide enough relief for patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

An Evolving Definition

The definition for RA remission continues to evolve as treatments change, Dr. Felson said. Today, some researchers continue to use the DAS28-CRP to define remission, and others still question whether it is appropriate to include a PRO when assessing remission.

“I’m troubled that we can define RA without asking how patients are doing,” Dr. Felson said. “This is the RA outcome most sensitive to change.”

Use of the DAS28 may continue today because of its lenient definition of remission. This makes it easier to achieve a difference between two types of therapy, Dr. Felson explained.

This year, ACR/EULAR approved a definition of remission that is no longer provisional.2 Under the new definition, the patient global assessment of arthritis activity must be 2 or less on a 0 to 10 scale.

Dr. Felson advised attendees to use the ACR/EULAR definition of remission in trials. A version excluding CRP is available for practice. He added that journals affiliated with the ACR or EULAR will not publish trials that only use the DAS28 to define RA remission.

Page: 1 2 | Single Page
Share: 

Filed under:Rheumatoid Arthritis Tagged with:ACR-FDA SummitACR/EULARRemission CriteriaRheumatoid Arthritis (RA)

Related Articles

    Remission Definitions in RA: Common Questions & Implications for Clinical Practice

    May 5, 2022

    A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.

    Target Remission

    March 1, 2007

    Strategies to identify and track remission in your RA patients

    A Passion for Multidisciplinary Collaboration

    February 3, 2012

    Through teamwork, David T. Felson, MD, MPH, has advanced understanding and treatment of rheumatic diseases

    New Criteria for RA Remission

    February 12, 2011

    ACR and EULAR update 1981 criteria to reflect modern treatment options

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences